Press Releases

View: All Categories General Releases Financial Releases Year: All Years 2009 2008 2007 2006 2005 2004 All Releases Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer Jun 22, 2009 13.7 KB   SEATTLE, Jun 22, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that Merck KGaA of Darmstadt, Germany, has initiated a global Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine, L-BLP25) in patients with hormone receptor-positive, locally advanced, recurrent or metastati... Read more Oncothyreon appoints Scott Peterson as Vice President of Research and Development Jun 15, 2009 12.1 KB   SEATTLE, Jun 15, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced the appointment of Scott Peterson, Ph.D., as Vice President, Research and Development at Oncothyreon. In this position, Dr. Peterson will be responsible for overseeing those pre-clinical and non-clinical resea... Read more Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting May 30, 2009 17.0 KB   SEATTLE, WA, May 30, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that data from clinical trials for three of the Company's product candidates were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 30, 2009 in Orlando, Florida. The prese... Read more Oncothyreon announces closing of $11.1 million registered direct financing May 27, 2009 9.8 KB   SEATTLE, May 27, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it closed its previously announced sale of 3,878,993 shares of its common stock and warrants to purchase 2,909,244 shares of its common stock for gross proceeds of approximately $11.1 million on May 26, 2009. Oncothyreo... Read more Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing May 20, 2009 10.0 KB   SEATTLE, May 20, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it has obtained commitments from several investors to purchase approximately 3.88 million shares of its common stock and warrants to purchase approximately 2.91 million shares of its common stock for gross proceeds of a... Read more Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis May 18, 2009 12.9 KB   SEATTLE, May 18, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) today announced the presentation of data demonstrating the effectiveness of Oncothyreon's PX-866 in a preclinical model of pulmonary fibrosis. The data were presented earlier today by William D. Hardie, M.D., Associate Professor, Pulmonary ... Read more Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting May 18, 2009 12.2 KB   SEATTLE, May 18, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) today announced upcoming presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29-June 2, 2009 in Orlando, Florida. Abstracts related to our product candidates Stimuvax(R), PX-866 and PX-12 are now a... Read more Oncothyreon reports first quarter 2009 financial results May 14, 2009 14.9 KB   SEATTLE, May 14, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) (the "Company") today reported a net loss of $2.5 million or $0.13 per basic and diluted share for the quarter ended March 31, 2009, compared with a net loss of $5.1 million or $0.26 per basic and diluted share for the comparable period in ... Read more Oncothyreon regains compliance with NASDAQ listing requirements Mar 16, 2009 10.3 KB   SEATTLE, Mar 16, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that on March 12, 2009, it received a notice from the NASDAQ Hearings Panel that Oncothyreon had re-gai... Read more Oncothyreon to present at Invest Northwest 2009 Mar 13, 2009 8.8 KB   SEATTLE, March 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Invest Nort... Read more Oncothyreon reports full year and fourth quarter 2008 financial results Mar 9, 2009 16.5 KB   SEATTLE, Mar 9, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) (the "Company") today reported financial results for the year and quarter ended December 31, 2008. Net income for the year ended December 31, 2008 was $7.1 million, or $0.37 per basic and $0.36 per diluted share, compared with a net loss... Read more Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call Mar 3, 2009 9.6 KB   SEATTLE, Mar 3, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its fourth quarter and year end 2008 financial results on Monday, March 9, 200... Read more Oncothyreon to present at BIO CEO & Investor Conference 2009 Feb 3, 2009 9.4 KB   SEATTLE, Feb. 3, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the 11th Annual BIO CE... Read more Oncothyreon announces development plans and personnel changes and updates financial guidance Dec 18, 2008 15.2 KB   SEATTLE, Dec. 18, 2008 (Canada NewsWire via COMTEX News Network) -- - Conference Call Scheduled for 1:30 p.m. Pacific Time Today - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that, in conjunction with the transfer of responsibility for the manufacture of Stimuvax(R) to Merck KGaA of Darmstadt, Germany announced pre... Read more Merck KGaA acquires manufacturing rights for Stimuvax from Oncothyreon Dec 18, 2008 14.0 KB   SEATTLE, Dec. 18, 2008 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) announced today that Merck KGaA of Darmstadt, Germany has licensed the right to manufacture Stimuvax(R) and, through its affiliate EMD Serono Canada Inc., purchased current inventory and certain assets utilized for the manufacture of Stimuv... Read more Oncothyreon reports third quarter 2008 financial results Nov 6, 2008 15.9 KB   SEATTLE, Nov. 6, 2008 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) (the "Company") today reported financial results for the quarter and nine months ending September 30, 2008. Total revenue was $0.8 million and $4.0 million for the three and nine month periods ended September 30, 2008, compared to $1.1 ... Read more Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference Nov 4, 2008 9.4 KB   SEATTLE, Nov. 4, 2008 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the Rodman ... Read more Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call Nov 3, 2008 9.6 KB   SEATTLE, Nov. 3, 2008 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its third quarter financial results on Thursday, November 6, 2008 after the c... Read more Oncothyreon to present at BIO Investor Forum 2008 Oct 24, 2008 9.4 KB   SEATTLE, Oct. 24, 2008 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the 7th An... Read more Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards Sep 17, 2008 12.4 KB   SEATTLE, Sep. 17, 2008 (Canada NewsWire via COMTEX News Network) -- On August 20, 2008 Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) disclosed that it had received a letter from The Nasdaq Stock Market indicating that (i) it did not comply with the requirements for continued listing on The NASDAQ Global Market because it did not meet the maintenance s... Read more Showing 1-20 of 146 Page: 1 2 3 ... 8  Next 20 = add release to Briefcase return to top ^